

## Lenalidomide Prescription Authorisation Form (PAF)

A newly completed copy of this form MUST accompany EVERY lenalidomide prescription. Completion of this information is mandatory for ALL patients. The completed form should be retained in the pharmacy.

|  |                               |                                 |                                    |                                |                                |                                |
|--|-------------------------------|---------------------------------|------------------------------------|--------------------------------|--------------------------------|--------------------------------|
| <b>Name of treating Hospital:</b>  |                               |                                 |                                    |                                |                                |                                |
| <b>Patient date of birth:</b> DD/MM/YYYY   |                               |                                 | <b>Patient ID number/Initials:</b> |                                |                                |                                |
| <b>Prescriber (PRINT):</b>   |                               |                                 |                                    |                                |                                |                                |
| <b>Supervising Physician:</b>  |                               |                                 |                                    |                                |                                |                                |
| <b>Indication (tick)</b>   |                               |                                 |                                    |                                |                                |                                |
| <input type="checkbox"/> Multiple Myeloma  |                               |                                 |                                    |                                |                                |                                |
| <input type="checkbox"/> Myelodysplastic Syndromes with isolated del5q cytogenetic abnormality   |                               |                                 |                                    |                                |                                |                                |
| <input type="checkbox"/> Mantle Cell Lymphoma relapsed and/or refractory   |                               |                                 |                                    |                                |                                |                                |
| <input type="checkbox"/> Follicular Lymphoma   |                               |                                 |                                    |                                |                                |                                |
| <input type="checkbox"/> Other (please specify) _____  |                               |                                 |                                    |                                |                                |                                |
| <b>Capsule strength prescribed (tick) / Quantity of capsules prescribed(*do not enter number of packs)</b>   |                               |                                 |                                    |                                |                                |                                |
| <input type="checkbox"/> 2.5 mg  | <input type="checkbox"/> 5 mg | <input type="checkbox"/> 7.5 mg | <input type="checkbox"/> 10 mg     | <input type="checkbox"/> 15 mg | <input type="checkbox"/> 20 mg | <input type="checkbox"/> 25 mg |
| Quantity*  | Quantity*                     | Quantity*                       | Quantity*                          | Quantity*                      | Quantity*                      | Quantity*                      |
| <b>Number of cycles prescribed:</b>  |                               |                                 |                                    |                                |                                |                                |
| <b>Please tick all boxes that apply</b>  |                               |                                 |                                    |                                |                                |                                |
| <b>Woman of non-childbearing potential</b>   |                               |                                 | TICK                               |                                |                                |                                |
| <b>Male</b>  |                               |                                 | TICK                               |                                |                                |                                |
| <b>The patient has been counselled about the teratogenic risk of treatment with lenalidomide and understands the need to use a condom if involved in sexual activity with a woman of childbearing potential not using effective contraception or if their partner is pregnant (even if the patient has had a vasectomy).</b> |                               |                                 |                                    | Y                              | N                              |                                |
| <b>Note to pharmacists – do not dispense unless ticked 'Y' for male patients</b>   |                               |                                 |                                    |                                |                                |                                |
| <b>Woman of childbearing potential</b>   |                               |                                 | TICK                               |                                |                                |                                |
| <b>The patient has been counselled about the teratogenic risk of treatment and the need to avoid pregnancy, and has been on effective contraception for at least 4 weeks or committed to absolute and continuous abstinence confirmed on a monthly basis.</b>  |                               |                                 |                                    | Y                              | N                              |                                |
| <b>Date of last negative pregnancy test</b>  |                               |                                 |                                    | DD                             | MM                             | YYYY                           |
| <b>Note to pharmacists – do not dispense unless ticked 'Y' and a negative test has been conducted within 3 days prior of the prescription date and dispensing is taking place within 7 days of the prescription date</b>   |                               |                                 |                                    |                                |                                |                                |

**Both signatures must be present prior to dispensing lenalidomide.**

### Prescriber's declaration

As the Prescriber, I have read and understood the lenalidomide Healthcare Professional's Information Guide. I confirm the information provided on this PAF is accurate, complete and in accordance with the requirements of the Pregnancy Prevention Programme for lenalidomide. I confirm treatment has been initiated and is monitored under the supervision of a physician with expertise in managing immunomodulatory or chemotherapeutic agents.

|                 |              |
|-----------------|--------------|
| Sign            | Print        |
| Date DD MM YYYY | Block number |

### Pharmacist's declaration

I am satisfied that this **Lenalidomide** Prescription Authorisation Form has been completed fully and that I have read and understood the **Lenalidomide** Healthcare Professional's Information Guide. For women of childbearing potential, dispensing will be taking place within 7 days of the date of prescription. I am dispensing no more than a 4 weeks supply to women of childbearing potential and 12 weeks for males and women of non-childbearing potential.

|                                     |            |
|-------------------------------------|------------|
| Sign                                | Print      |
| Date                                | DD MM YYYY |
| Name of dispensing pharmacy         |            |
| <b>Lenalidomide Brand dispensed</b> |            |